NHS expands abiraterone access for high-risk prostate
NHS England has widened abiraterone acetate access for adults with high-risk non-metastatic prostate cancer, with treatment expected to reach eligible patients within weeks. The change matters because trials show higher 6-year survival and fewer progressions to incurable spread when abiraterone is used earlier alongside standard care. It also removes a long-running access gap that left […]
Pharmacogenomics Shapes Safer NHS Prescribing in 2026
The NHS has entered a decisive phase in the use of pharmacogenomics, moving from targeted pilots to routine medicines optimisation informed by genetic data. By 2026, evidence from national implementation programmes shows that pharmacogenomic testing can materially reduce adverse drug reactions and improve therapeutic response when embedded directly into clinical workflows. The promise of delivering […]
Personalised medicines: the new frontier, the rise of CRISPR-based therapies in oncology
The first regulatory approvals for a CRISPR-based medicine in the UK and EU marked a turning point for genomic medicine and set expectations for oncology. In 2023, the MHRA licensed exagamglogene autotemcel, branded Casgevy, for severe sickle cell disease, and later the EMA approved it for use in the EU. NICE has since recommended Casgevy […]
AI speeds drug discovery as pharma takes risks in 2026
In 2026, the pharmaceutical sector is moving back into a risk on posture, with AI drug discovery shifting from promise to operational impact and a tightening patent cliff timeline pushing capital towards late stage assets. For researchers and industry professionals, the practical benefit is clear. The next 12 months are likely to bring faster target […]
UK clinical trials pay surges in 2026
The United Kingdom enters 2026 as one of the most active environments in the world for high-paying clinical trials, particularly early phase studies involving healthy volunteers. Regulatory reforms, faster approvals and a strong pipeline in oncology, metabolic disease and infection research are increasing both the volume and the financial value of opportunities. At the same […]
The Role of Cathepsin B (CTSB) in Immune Response Studies
Cathepsin B (CTSB) is a lysosomal cysteine protease that plays a key role in protein turnover, antigen processing, and immune regulation. It is widely expressed across mammalian tissues. Recent research demonstrates that Cathepsin B Protein (CTSB) also plays a critical role in both innate and adaptive immune responses. It is involved in: Structure and Function […]
Stem Cell Therapy for Type 1 Diabetes: Toward a Functional Cure
For over a century, the discovery of insulin transformed Type 1 Diabetes (T1D) from a fatal diagnosis into a survivable condition. Yet, despite remarkable technological advances, patients remain tethered to an intensive daily regimen of blood glucose monitoring and insulin administration. Now, for the first time, regenerative medicine may be close to offering a different […]
A Complete Guide to T-Cell Cytotoxicity Assays for Immunology and Immunotherapy Research
The human immune system is a complex network of cells, tissues, and signaling molecules that serves as a defense system. It continuously identifies and eliminates viruses, bacteria, abnormal cells, and other harmful threats. Among other types of immune cells, T cells play a critical role. A type of white blood cell, T cells (T lymphocytes) […]
Beyond the pill: how digital therapeutics are transforming chronic care in the NHS
Chronic illness drives demand across the NHS and shapes budgets, workforce planning and service design. People living with multiple long-term conditions account for around half of hospital admissions, outpatient visits and primary care consultations, and a large share of prescribing costs. Multimorbidity is rising, with projections of substantial growth in major illnesses by 2040. This […]
Are bacteriophage therapies the answer to antibiotic resistance
Antimicrobial resistance is accelerating across health systems and undermining routine care. Surgical prophylaxis, oncology regimens and neonatal medicine all depend on reliable antibiotics, yet resistant pathogens are eroding that foundation. In 2025, health services are searching for modalities that complement or bypass failing drugs. Bacteriophage therapy sits near the top of that shortlist because it […]